以核酸适体KMF2-1a为基础的乳腺癌细胞靶向化疗药物载体研究
作者:
作者单位:

作者简介:

孙维佳, Email: sunweijia2009@126.com

通讯作者:

中图分类号:

R737.9

基金项目:

湖南省科技厅科研资助项目(2010TP4053)。


Aptamer KMF2-1a-based chemotherapeutic drug carrier targeting breast cancer cells
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨开发以核酸适体KMF2-1a为基础的乳腺癌细胞靶向阿霉素载体的可行性。 方法:应用流式细胞仪检测人乳腺癌MCF-10AT1细胞对核酸适体KMF2-1a及其修饰物(药物载体)的内吞作用;将阿霉素与药物载体相互作用后,用分光光度计检测阿霉素嵌入药物载体的情况。 结果:流式细胞仪检测示,核酸适体KMF2-1a及其修饰物均能被MCF-10AT1细胞特异内吞;分光光度仪检测示,阿霉素可成功嵌入至药物载体中。 结论:核酸适体KMF2-1a能被MCF-10AT1细胞特异内吞,经修饰后有可能作为阿霉素的载体用于乳腺癌的靶向治疗。

    Abstract:

    Objective: To investigate the feasibility of the development of aptamer KMF2-1a-based doxorubicin carrier that targets breast cancer cells. Methods: The internalization efficacies of aptamer KMF2-1a and its modified product (drug carrier) into human breast cancer MCF-10AT1 cells were tested by flow cytometry analysis. The incorporation of doxorubicin into the drug carrier was determined by spectrophotometer analysis after their interaction. Results: Flow cytometry analysis showed that both aptamer KMF2-1a and its modified product could be specifically internalized by MCF-10AT1 cells. Spectrophotometer detection demonstrated that doxorubicin was successfully incorporated into the drug carrier. Conclusion: Aptamer KMF2-1a can be internalized specifically by MCF-10AT1 cells, and it can be potentially used as a doxorubicin carrier after modification for targeted breast cancer therapy.

    参考文献
    相似文献
    引证文献
引用本文

张克兢|唐利立|孙维佳.以核酸适体KMF2-1a为基础的乳腺癌细胞靶向化疗药物载体研究[J].中国普通外科杂志,2013,22(5):618-623.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2012-12-06
  • 最后修改日期:2013-04-11
  • 录用日期:
  • 在线发布日期: 2013-05-15
  • 出版日期:
新投稿系统运行通知

作者投稿请直接点击左侧“作者登录”,请不要进入旧版入口。如登录或投稿中遇到任何问题,请联系电话13311390237。谢谢!

关闭